CHSJ

Curr Health Sci J, vol. 42, no. 2, 2016

Adalimumab and Infliximab in Crohn`s disease-real life data from a national retrospective cohort study

[Original Paper]

C. PREDA(1), L. FULGER(1), L. GHEORGHE(1), C. GHEORGHE(1), A. GOLDIS(2), A. TRIFAN(3), M. TANTAU(4), A. TANTAU(4), L. NEGREANU(5), M. MANUC(1), C. CIJEVSCHI-PRELIPCEAN(3), R. IACOB(1), C. TIERANU(1), C. MEIANU(1), M. DICULESCU(1)


(1)Clinic Fundeni Institute, Gastroenterology & Hepatology, Bucharest;
(2)University of Medicine "Victor Babes", Clinic of Gastroenterology, Timisoara;
(3)Clinic County Hospital “Sf.Spiridon”, Gastroenterology and Hepatology, Iassy;
(4)Regional Institute of Gastroenterology and Hepatology “O.Fodor”, Gastroenterology and Hepatology, Cluj;
(5)Clinic Universitary Emergency Hospital, Bucharest


Abstract:

Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic regression was performed with the statistical program Minitab. Results: Patients were half women, with a median age of 36, a median disease duration of 2.5 years, 80% received Azathioprine. Mean therapy duration was 20 months in ADA group and 36 months in IFX group. Complete response to Adalimumab respectively Infliximab was recorded in 77%vs.65%, secondary loss of response in 18%vs.28%, statistically comparable. We failed to identify predictors of response. In 79.2%of patients with secondary loss of response to ADA, the dose was escalated, 12.5% were switched to Infliximab. In 70%of patients that lost response to IFX, the dose was increased, 30% were switched to Adalimumab. Conclusions: Adalimumab and Infliximab have similar efficacy, with a complete response rate of~70%. In case of secondary loss of response to IFX, the best solution is to switch to ADA, with 83% response rate, while in case of secondary loss of response to ADA, increasing the dose leads to 84 % response rate.


Keywords: Adalimumab, Infliximab, Crohn`s disease



Corresponding: Preda Carmen- Monica, Clinic Fundeni Institute, Gastroenterology&Hepatology, Sos. Fundeni 258, 22328, Bucharest, Romania; Phone: 0040212750558, Fax: 0040213180447; e-mail: preda_monicaa@yahoo.com


DOI 10.12865/CHSJ.42.02.01 - Download PDF
current issue cover Download cover
Download contents

Journal archive